Promino cuts losses to $3M in 2025 with $2.1M revenue, boosts production and expands muscle health product sales

Promino Nutritional Sciences reported a significant improvement in its 2025 financial results, with revenue rising to over $2.1 million from about $260,600 in 2024, and net loss shrinking from $7.1 million to $3.0 million. The company expanded distribution of its core product, Rejuvenate Muscle Health™, supported by growth in e-commerce and retail channels. Cost management efforts reduced expenses to $3.4 million from $6.3 million the previous year. Promino also enhanced its financial reporting and governance after lifting a cease-trade order and initiated a large production run to meet anticipated demand. These steps position the company for disciplined growth and operational strengthening in the muscle health nutrition market.